Spyglass Capital Management LLC Has $63.74 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Spyglass Capital Management LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 115.9% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 120,365 shares of the company’s stock after acquiring an additional 64,610 shares during the quarter. Medpace comprises 3.5% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. Spyglass Capital Management LLC’s holdings in Medpace were worth $63,744,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. American Capital Management Inc. acquired a new position in shares of Medpace in the second quarter valued at about $111,329,000. California State Teachers Retirement System increased its position in Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after acquiring an additional 4,719 shares during the period. Focus Partners Advisor Solutions LLC acquired a new stake in Medpace in the 2nd quarter worth about $1,685,000. BlackRock Inc. acquired a new stake in Medpace in the 2nd quarter worth about $1,323,047,000. Finally, Rice Hall James & Associates LLC bought a new stake in Medpace in the 2nd quarter valued at about $28,659,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. TD Cowen increased their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $584.18.

Medpace Trading Down 1.1%

NASDAQ MEDP opened at $593.99 on Tuesday. The firm’s 50 day simple moving average is $568.10 and its 200 day simple moving average is $495.34. The firm has a market capitalization of $16.58 billion, a price-to-earnings ratio of 34.82, a P/E/G ratio of 2.68 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period in the previous year, the business earned $3.10 earnings per share. The company’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 27,174 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the transaction, the chief executive officer owned 561,195 shares of the company’s stock, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 134,471 shares of company stock worth $82,151,311. 20.50% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.